Abstract:With the indepth studies of molecular mechanisms of renal cell carcinoma (RCC), people have made great progress in the targeted therapy drugs which targeted at vascular endothelial growth factor (VEGF) and their receptors, which dramatically improve the treatment outcome for patients with advanced or metastatic RCC. However, recent clinical trails show that the targeted therapy drugs may cause adverse events, such as hypertension, bone marrow toxicity, pneumonitis and so on. It is important to manage the adverse events promptly not only to improve the therapeutic efficacy but also to improve the quality of life for patients with RCC.

Key words:Kidney neoplasms,Drug therapy,Adverse effects